Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
1200 participants
INTERVENTIONAL
2025-12-10
2026-02-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will:
Read 6 fictional brain MRI reports online. Answer questions to check if they understood the results. Rate their satisfaction and if they feel they would need to ask a doctor for help.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Design This is a randomized, controlled, single-blind trial nested within the COMPARE e-cohort. The study uses a parallel-group design with a 1:1 allocation ratio. The entire study is conducted remotely via secure online forms.
Participants The study recruits adult volunteers already enrolled in the COMPARE e-cohort. Participants must have sufficient proficiency in written French to read the reports and complete the questionnaires. No specific medical condition is required for inclusion, as the study uses fictional case scenarios.
Intervention and Procedures Participants are randomized to one of two groups via a minimization procedure balancing history of brain MRI and known neurological pathology. Each participant is asked to read six fictional brain MRI reports simulating common emergency headache scenarios. The six reports cover three clinical situations: two with normal results, two with incidental findings not explaining the headache, and two with abnormalities explaining the headache. In the experimental group, participants receive the standard MRI report enriched with a structured summary paragraph generated by an open-weights LLM, inserted under the section Synthesis for the patient and non-radiologist physician. In the control group, participants receive the standard MRI report in its native version without the AI-generated summary.
Outcome Measures Immediately after reading each report, participants complete a standardized questionnaire. The primary outcome is the comprehension of the report, measured by the accuracy of the response to the binary question: Is a probable explanation for the headache found in this report? Secondary outcomes include participant satisfaction measured on a Likert scale, perceived need for professional clarification, perceived ability to explain results to a relative, and projected anxiety levels.
Statistical Analysis The primary analysis will compare the proportion of correct responses between groups using a mixed logistic regression model. This model will include the intervention group as a fixed effect and account for crossed random effects (participant and report) to manage intra-individual correlation and variability between clinical cases. The sample size is calculated to be 412 participants (206 per group) to detect a 10% difference in understanding with 95% power.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Original MRI reports
No interventions assigned to this group
LLM-generated summaries in addition to the original reports
LLM-generated lay summary
Participants assigned to this group read fictional brain MRI reports that include an additional summary paragraph generated by an artificial intelligence tool. Specifically, an open-weights Large Language Model (LLM) with fewer than 100 billion parameters is used, hosted locally on a secure server to ensure data privacy. This model generates a short synthesis designed to be clear and structured for non-medical readers. This summary is inserted into the report under the heading Synthesis intended for the patient and non-radiologist physician. The intervention consists solely of this added text; the standard medical content of the report remains unchanged.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LLM-generated lay summary
Participants assigned to this group read fictional brain MRI reports that include an additional summary paragraph generated by an artificial intelligence tool. Specifically, an open-weights Large Language Model (LLM) with fewer than 100 billion parameters is used, hosted locally on a secure server to ensure data privacy. This model generates a short synthesis designed to be clear and structured for non-medical readers. This summary is inserted into the report under the heading Synthesis intended for the patient and non-radiologist physician. The intervention consists solely of this added text; the standard medical content of the report remains unchanged.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Direction Générale de l'offre de Soins (DGOS)
UNKNOWN
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aghiles.HAMROUN
Head of the Include Health Data Warehouse, Lille university Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-3783
Identifier Type: -
Identifier Source: org_study_id